Pulmonx (LUNG) Net Cash Flow (2019 - 2025)

Pulmonx (LUNG) has reported Net Cash Flow for 7 consecutive years, with $722000.0 the latest figure, recorded in Q3 2025.

• On a quarterly basis, Net Cash Flow rose 23966.67% year-over-year to $722000.0 in Q3 2025; TTM through Sep 2025 was $13.4 million, a 142.8% increase from a year earlier, with the FY2024 full-year figure at -$12.7 million, up 30.3% from the prior year.
• Net Cash Flow was $722000.0 for Q3 2025 at Pulmonx, down from $1.5 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $8.6 million in Q1 2023 and troughed at -$39.7 million in Q4 2021.
• A 5-year average of -$8.2 million and a median of -$8.6 million in 2023 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow sank 1598.18% in 2021 and jumped 23966.67% in 2025, its largest moves.
• Over 5 years, Net Cash Flow stood at -$39.7 million in 2021, then soared by 73.64% to -$10.5 million in 2022, then fell by 6.58% to -$11.1 million in 2023, then jumped by 166.37% to $7.4 million in 2024, then sank by 90.24% to $722000.0 in 2025.
• The last three Net Cash Flow figures came in at $722000.0 (Q3 2025), $1.5 million (Q2 2025), and $3.8 million (Q1 2025), per Business Quant data.